161 related articles for article (PubMed ID: 23470981)
1. A truncated diphtheria toxin based recombinant porcine CTLA-4 fusion toxin.
Peraino JS; Schenk M; Zhang H; Li G; Hermanrud CE; Neville DM; Sachs DH; Huang CA; Duran-Struuck R; Wang Z
J Immunol Methods; 2013 May; 391(1-2):103-11. PubMed ID: 23470981
[TBL] [Abstract][Full Text] [Related]
2. Development of a diphtheria toxin-based recombinant porcine IL-2 fusion toxin for depleting porcine CD25+ cells.
Peraino JS; Schenk M; Li G; Zhang H; Farkash EA; Sachs DH; Huang CA; Duran-Struuck R; Wang Z
J Immunol Methods; 2013 Dec; 398-399():33-43. PubMed ID: 24055128
[TBL] [Abstract][Full Text] [Related]
3. Expression and purification of soluble porcine CTLA-4 in yeast Pichia pastoris.
Peraino J; Zhang H; Hermanrud CE; Li G; Sachs DH; Huang CA; Wang Z
Protein Expr Purif; 2012 Apr; 82(2):270-8. PubMed ID: 22326797
[TBL] [Abstract][Full Text] [Related]
4. Diphtheria toxin-based bivalent human IL-2 fusion toxin with improved efficacy for targeting human CD25(+) cells.
Peraino JS; Zhang H; Rajasekera PV; Wei M; Madsen JC; Sachs DH; Huang CA; Wang Z
J Immunol Methods; 2014 Mar; 405():57-66. PubMed ID: 24462799
[TBL] [Abstract][Full Text] [Related]
5. Ontak-like human IL-2 fusion toxin.
Wang Z; Zheng Q; Zhang H; Bronson RT; Madsen JC; Sachs DH; Huang CA; Wang Z
J Immunol Methods; 2017 Sep; 448():51-58. PubMed ID: 28551309
[TBL] [Abstract][Full Text] [Related]
6. Diphtheria toxin-based recombinant murine IL-2 fusion toxin for depleting murine regulatory T cells in vivo.
Wei M; Marino J; Trowell A; Zhang H; Stromp Peraino J; Rajasekera PV; Madsen JC; Sachs DH; Huang CA; Benichou G; Wang Z
Protein Eng Des Sel; 2014 Sep; 27(9):289-95. PubMed ID: 25147093
[TBL] [Abstract][Full Text] [Related]
7. Diphtheria-toxin based anti-human CCR4 immunotoxin for targeting human CCR4(+) cells in vivo.
Wang Z; Wei M; Zhang H; Chen H; Germana S; Huang CA; Madsen JC; Sachs DH; Wang Z
Mol Oncol; 2015 Aug; 9(7):1458-70. PubMed ID: 25958791
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of cross-species reactivities of human versus porcine CTLA-4.
Peraino JS; Zhang H; Li G; Huang CA; Wang Z
Hum Immunol; 2013 Jul; 74(7):842-8. PubMed ID: 23602875
[TBL] [Abstract][Full Text] [Related]
9. Reactivity of murine cytokine fusion toxin, diphtheria toxin390-murine interleukin-3 (DT390-mIL-3), with bone marrow progenitor cells.
Chan CH; Blazar BR; Greenfield L; Kreitman RJ; Vallera DA
Blood; 1996 Aug; 88(4):1445-56. PubMed ID: 8695865
[TBL] [Abstract][Full Text] [Related]
10. Development of a diphtheria toxin based antiporcine CD3 recombinant immunotoxin.
Wang Z; Duran-Struuck R; Crepeau R; Matar A; Hanekamp I; Srinivasan S; Neville DM; Sachs DH; Huang CA
Bioconjug Chem; 2011 Oct; 22(10):2014-20. PubMed ID: 21866954
[TBL] [Abstract][Full Text] [Related]
11. Diphtheria toxin-based anti-human CD19 immunotoxin for targeting human CD19
Zheng Q; Wang Z; Zhang H; Huang Q; Madsen JC; Sachs DH; Huang CA; Wang Z
Mol Oncol; 2017 May; 11(5):584-594. PubMed ID: 28306193
[TBL] [Abstract][Full Text] [Related]
12. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody.
Vanhove B; Laflamme G; Coulon F; Mougin M; Vusio P; Haspot F; Tiollier J; Soulillou JP
Blood; 2003 Jul; 102(2):564-70. PubMed ID: 12649149
[TBL] [Abstract][Full Text] [Related]
13. Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor.
Vallera DA; Panoskaltsis-Mortari A; Jost C; Ramakrishnan S; Eide CR; Kreitman RJ; Nicholls PJ; Pennell C; Blazar BR
Blood; 1996 Sep; 88(6):2342-53. PubMed ID: 8822957
[TBL] [Abstract][Full Text] [Related]
14. Modified DT-IL2 fusion toxin targeting uniquely IL2Ralpha expressing leukemia cell lines - Construction and characterization.
Potala S; Verma RS
J Biotechnol; 2010 Jul; 148(2-3):147-55. PubMed ID: 20580754
[TBL] [Abstract][Full Text] [Related]
15. Non-glycosylated human B7-1(CD80) retains the capacity to bind its counter-receptors.
Chen A; Meyerson HJ; Salvekar A; Tykocinski ML
FEBS Lett; 1998 May; 428(3):127-34. PubMed ID: 9654121
[TBL] [Abstract][Full Text] [Related]
16. Recombinant immunotoxins for treating cancer.
FitzGerald DJ; Kreitman R; Wilson W; Squires D; Pastan I
Int J Med Microbiol; 2004 Apr; 293(7-8):577-82. PubMed ID: 15149034
[TBL] [Abstract][Full Text] [Related]
17. The effects of helix breaking mutations in the diphtheria toxin transmembrane domain helix layers of the fusion toxin DAB389IL-2.
Hu HY; Huynh PD; Murphy JR; vanderSpek JC
Protein Eng; 1998 Sep; 11(9):811-7. PubMed ID: 9796831
[TBL] [Abstract][Full Text] [Related]
18. Targeted introduction of a diphtheria toxin resistant mutation into the chromosomal EF-2 locus of Pichia pastoris and expression of immunotoxin in the EF-2 mutants.
Liu YY; Woo JH; Neville DM
Protein Expr Purif; 2003 Aug; 30(2):262-74. PubMed ID: 12880776
[TBL] [Abstract][Full Text] [Related]
19. Diphtheria toxin receptor-binding domain substitution with interleukin 6: genetic construction and interleukin 6 receptor-specific action of a diphtheria toxin-related interleukin 6 fusion protein.
Jean LF; Murphy JR
Protein Eng; 1991 Dec; 4(8):989-94. PubMed ID: 1817263
[TBL] [Abstract][Full Text] [Related]
20. Improvement of a recombinant anti-monkey anti-CD3 diphtheria toxin based immunotoxin by yeast display affinity maturation of the scFv.
Wang Z; Kim GB; Woo JH; Liu YY; Mathias A; Stavrou S; Neville DM
Bioconjug Chem; 2007; 18(3):947-55. PubMed ID: 17352456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
